Trial
NCT05580770
Mirdametinib + BGB-3245 in Advanced Solid Tumors
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
SpringWorks Therapeutics, Inc.
Collaborators
—
Condition
Advanced Solid Tumor
Intervention
Mirdametinib 2mg
Why stopped
Lack of tolerability of BGB-3245 (Brimarafenib) when given in combination with Mirdametinib
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-11